Product to be Launched in the U.S. in the Second Quarter of 2009 LAVAL, QC, Dec. 31 (HSMN NewsFeed) - Labopharm Inc. (TSX: DDS ; NASDAQ: DDSS ) today announced that RYZOLT(TM) (tramadol HCl extended release tablets), Labopharm’s once-daily formulation…
Biopharmaceuticals, FDA
Labopharm, tramadol, RYZOLT

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain”
Leave a Comment